Wacker Chemie (WCH) Investor presentation summary

Business overview and strategy

• Operates globally with 27 production sites and €5.5bn in 2025 sales, focusing on specialty chemicals, polysilicon, polymers, and biosolutions.

• Maintains leading market positions: No. 1 in polysilicon for semiconductors, No. 1 in polymers, No. 2 in silicones, and niche leadership in biosolutions.

• Diversified end markets include construction, healthcare, electronics, energy, and transportation.

• Over 60% of sales generated outside Europe, with strong presence in Asia and the Americas.

• Strategic focus on expanding specialty business, advancing biotech, digitalization, and sustainability.

Financial performance and outlook

• 2025 sales reached €5.5bn with EBITDA of €427m, impacted by restructuring expenses.

• Q2 2026 sales rose 7% year-over-year to €1.52bn; EBITDA before specials up 53% to €175m, driven by cost savings and higher volumes.

• Net income in Q2 2026 was €350m, boosted by Siltronic share sale and valuation effects.

• FY 2026 outlook: sales expected to grow mid-single-digit percent, EBITDA guided at €625–750m, net financial debt around €500m.

• Maintains strong liquidity (€1.57bn) and equity (€4.18bn), with net debt at €722m as of June 2026.

Segment performance

• Silicones: EBITDA up 18% in Q2 2026, supported by cost program and positive mix; sales and margins expected to rise for FY 2026.

• Polymers: Q2 2026 EBITDA up 74% year-over-year, driven by pricing, cost savings, and inventory effects.

• Biosolutions: Sales and EBITDA improved year-over-year in Q2 2026, with strong project business in BioPharma.

• Polysilicon: Strong semiconductor demand, weak solar market; Q2 2026 EBITDA down due to lower solar pricing and higher energy costs.